Koeppen H - Search Results

1

The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo.

DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. DeAlmeida VI, et al. Among authors: koeppen h. Cancer Res. 2007 Jun 1;67(11):5371-9. doi: 10.1158/0008-5472.CAN-07-0266. Cancer Res. 2007. PMID: 17545618

2

Dynamics of notch expression during murine prostate development and tumorigenesis.

Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Shou J, et al. Among authors: koeppen h. Cancer Res. 2001 Oct 1;61(19):7291-7. Cancer Res. 2001. PMID: 11585768

3

Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.

Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H. Ross S, et al. Among authors: koeppen h. Cancer Res. 2002 May 1;62(9):2546-53. Cancer Res. 2002. PMID: 11980648

4

Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.

Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D. Mendoza N, et al. Among authors: koeppen h. Cancer Res. 2003 Mar 1;63(5):1020-4. Cancer Res. 2003. PMID: 12615717

5

EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer.

Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, Chui C, Franz G, Senter P, Koeppen H, Polakis P. Mao W, et al. Among authors: koeppen h. Cancer Res. 2004 Feb 1;64(3):781-8. doi: 10.1158/0008-5472.can-03-1047. Cancer Res. 2004. PMID: 14871799

6

HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.

Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, Erickson S. Finkle D, et al. Among authors: koeppen h. Clin Cancer Res. 2004 Apr 1;10(7):2499-511. doi: 10.1158/1078-0432.ccr-03-0448. Clin Cancer Res. 2004. PMID: 15073130

7

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A. Jin H, et al. Among authors: koeppen h. Cancer Res. 2004 Jul 15;64(14):4900-5. doi: 10.1158/0008-5472.CAN-04-0408. Cancer Res. 2004. PMID: 15256461

8

COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.

Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, French DM. Dornan D, et al. Among authors: koeppen h. Cancer Res. 2004 Oct 15;64(20):7226-30. doi: 10.1158/0008-5472.CAN-04-2601. Cancer Res. 2004. PMID: 15492238

9

EphB2 is a prognostic factor in colorectal cancer.

Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P, Koeppen H. Jubb AM, et al. Among authors: koeppen h. Clin Cancer Res. 2005 Jul 15;11(14):5181-7. doi: 10.1158/1078-0432.CCR-05-0143. Clin Cancer Res. 2005. PMID: 16033834

10

Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers.

Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, de Sauvage FJ, Davis DP. Gray D, et al. Among authors: koeppen h. Cancer Res. 2005 Nov 1;65(21):9751-61. doi: 10.1158/0008-5472.CAN-04-4531. Cancer Res. 2005. PMID: 16266996

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters